# DoD Peer Reviewed Alzheimer’s Research Program, Accelerating Diagnostics Research Award

Source: https://welltoldgrants.com/grants/w81xwh-22-prarp-adra-dod-peer-reviewed-alzheimers-research-program-accelerating/  
Official notice: https://www.grants.gov/search-results-detail/339694

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 2 awards worth $5.0 million in total. Applications closed on July 25, 2022.

| Field | Value |
|---|---|
| Opportunity number | W81XWH-22-PRARP-ADRA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | July 25, 2022 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 2 |
| Total funding | $5.0 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The intent of the FY22 PRARP ADRA is to support high-impact advancement of robust diagnostic and/or prognostic factors pertaining to AD/ADRD following military service and/or TBI. Applications meeting the intent of this mechanism will accelerate clinically useful factors for rapid transfer to clinical practice to bridge a critical gap between identification of relevant factors and clinical usage. The proposed factors for investigation must correlate with clinical endpoints relevant to AD/ADRD following military service and/or TBI. Inclusion of preliminary data is required. Applicants should clearly describe the intent, purpose, as well as the clinical and practical utility of the diagnostic and/or prognostic factors being studied. Considerations for how the diagnostic/prognostic factors meaningfully inform care and disease management should be described both at the provider and individual living with AD/ADRD level. As part of the application, the proposed prognostic or diagnostic factors should demonstrate their potential for improved specificity and sensitivity with respect to diagnosis and/or prognosis of AD/ADRD as the study endpoint. Additionally, applications should address the utility of the diagnostic/ prognostic factor(s) in rural or resource-limited environments. Applications may consider elements of biomarker and risk factor validation as part of the application, particularly if validation is intended to widen the diversity of the population to which the factors/biomarkers will be applicable. Biomarker validation is defined as assessing the biomarker’s measurement performance characteristics in terms of reproducibility, accuracy, precision, and limits of sensitivity. Risk factors may include modifiable and non-modifiable factors that influence a person’s likelihood to develop AD/ADRD. Clinical trials are not allowed; however, the FY22 ADRA may use data and/or human anatomical substances from an existing clinical trial to carry out the research.

## Questions people ask

### Is W81XWH-22-PRARP-ADRA still open?

No. It closed on July 25, 2022. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoD Peer Reviewed Alzheimer’s Research Program, Accelerating Diagnostics Research Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoD Peer Reviewed Alzheimer’s Research Program, Accelerating Diagnostics Research Award?

Closed July 25, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $5.0 million in total across about 2 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.